Relapsed or Refractory Multiple Myeloma Video Perspectives

In this video interview, Sham Mailankody, MBBS, medical oncologist at Memorial Sloan Kettering Cancer Center, discussed:

• “new, exciting developments” in relapsed or refractory multiple myeloma, including BCMA-targeted treatments;
• how CAR-T has impacted the myeloma treatment landscape;
• treatments and areas of future research for triple-class refractory disease, like bispecific antibodies and an off-the-shelf BCMA-targeted CAR T-cell therapy;
• tracking markers of relapse in multiple myeloma; and
• methods used to help predict relapse, including those that show promise like mass spectrometry and using circulating tumor DNA.